Scardamaglia P, Carraro C, Mancino P, Stentella P
Centro di Laserchirurgia e Patologia Cervico-Vaginale, Università degli Studi "Sapienza", Roma, Italia.
Minerva Ginecol. 2010 Oct;62(5):389-93.
The aim of the study was to evaluate the effectiveness of the beta-glucan in women with abnormal cytology, including the women with a positive screening for ASCUS-LSIL furtherly divided in women with positive cytology (ASCUS or LSIL) and negative colposcopy and women with abnormal cytology, positive colposcopy and human papilloma virus (HPV)-CIN1 hystology who opted for follow-up.
From September 2007 to December 2008, 60 women with ASCUS-LSIL diagnosis were recruited at the ambulatory of Lasersurgery and Cervico-Vaginal Patology, Department of Gynecology and Obstetrics of Policlinico Umberto I of Rome. The women was subdivided in two groups: 1) women with cytological diagnosis of ASCUS or LSIL and negative colposcopy; 2) women with abnormal cytology, positive colposcopy and HPV-CIN1 histology, who opted for follow-up. All the women were treated with two cycles of a daily topical application of beta-glucan for 20 consecutive days with a suspension of 10 days. The effects of beta-glucan were analyzed with colposcopy and cytology at 3.6 and 12 months from the beginning of the therapy.
After 3 months of treatment, of the 30 women with positive cytology and negative colposcopy, 80% with ASCUS diagnosis resulted negative, 35% with LSIL diagnosis resulted negative; after 6 months 100% with ASCUS diagnosis resulted negative, 70% with LSIL diagnosis resulted negative; after 12 months 85% with LSIL diagnosis resulted negative. Of the 30 women with positive cytology, positive colposcopy and HPV-CIN1 histology after 3 months 20% resulted negative, after 6 months 60% resulted negative and after 12 months 80% resulted negative. The persistence of the HPV-CIN1 histology was verified in the 13% of the women. For these women the definitive treatment was the TFD.
Our study demonstrate the effectiveness of the treatment with beta-glucan in the women with ASCUS-LSIL lesions and HPV-CIN1 lesions, increasing of the regressions rate after 12 months of the treatment of the 15-20%.
本研究旨在评估β-葡聚糖对细胞学异常女性的疗效，其中包括ASCUS-LSIL筛查阳性的女性，这些女性进一步分为细胞学阳性（ASCUS或LSIL）且阴道镜检查阴性的女性，以及细胞学异常、阴道镜检查阳性且人乳头瘤病毒（HPV）-CIN1组织学类型且选择随访的女性。
2007年9月至2008年12月，在罗马翁贝托一世综合医院妇产科激光手术与宫颈-阴道病理学门诊招募了60例诊断为ASCUS-LSIL的女性。这些女性被分为两组：1）细胞学诊断为ASCUS或LSIL且阴道镜检查阴性的女性；2）细胞学异常、阴道镜检查阳性且HPV-CIN1组织学类型且选择随访的女性。所有女性均接受两个疗程的治疗，每日局部应用β-葡聚糖，连续20天，停药10天。在治疗开始后的3、6和12个月，通过阴道镜检查和细胞学检查分析β-葡聚糖的疗效。
治疗3个月后，在30例细胞学阳性且阴道镜检查阴性的女性中，诊断为ASCUS的女性80%结果转为阴性，诊断为LSIL的女性35%结果转为阴性；6个月后，诊断为ASCUS的女性100%结果转为阴性，诊断为LSIL的女性70%结果转为阴性；12个月后，诊断为LSIL的女性85%结果转为阴性。在30例细胞学阳性、阴道镜检查阳性且HPV-CIN1组织学类型的女性中，3个月后20%结果转为阴性，6个月后60%结果转为阴性，12个月后80%结果转为阴性。13%的女性HPV-CIN1组织学类型持续存在。对于这些女性，确定性治疗为全子宫双附件切除术。
我们的研究证明了β-葡聚糖治疗ASCUS-LSIL病变和HPV-CIN1病变女性的有效性，治疗12个月后消退率提高了15%-20%。
